Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3 Plasma cell 2 Classical hematology 2 Breast 2 Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Head & Neck 1 Gynecologic 1 Gastrointestinal 1 CNS 1

Conditions

Oligometastatic Disease 1

Interventions

Injections 54 pembrolizumab 40 Carboplatin 20 Bevacizumab 19 Cyclophosphamide 17 toripalimab 14 Nivolumab 14 Cisplatin 14 tislelizumab 13 fludarabine 13 Specimen Handling 13 Paclitaxel 13 Interviews as Topic 13 Pemetrexed 12 Standard of Care 11 Practice Guidelines as Topic 11 Oxaliplatin 11 Fluorouracil 10 Cetuximab 10 atezolizumab 9 Educational Status 9 Docetaxel 9 Capecitabine 9 Leucovorin 8 Methods 7 Etoposide 7 Early Intervention, Educational 7 spartalizumab 6 olaparib 6 Ipilimumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Tretinoin × Other solid neoplasm × Clear all

NCT06439888 2025-12-01

LySATRA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Other solid neoplasm

Oligometastatic Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡